Daniel Bradbury Sells 7,867 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 7,867 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total value of $221,613.39. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Daniel Bradbury also recently made the following trade(s):

• On Monday, January 6th, Daniel Bradbury sold 7,867 shares of Castle Biosciences stock. The shares were sold at an average price of $29.14, for a total transaction of $229,244.38.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock opened at $27.60 on Monday. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $28.20 and its two-hundred day moving average price is $28.91. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84. The stock has a market cap of $773.08 million, a PE ratio of 138.01 and a beta of 0.91.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Robert W. Baird lifted their price target on Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. BTIG Research boosted their price target on Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. KeyCorp increased their price target on Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Lake Street Capital lifted their price objective on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, Canaccord Genuity Group increased their target price on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $40.29.

Institutional Trading of Castle Biosciences

A number of large investors have recently added to or reduced their stakes in CSTL. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Castle Biosciences by 147.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company’s stock worth $4,719,000 after purchasing an additional 98,571 shares during the period. Harbor Capital Advisors Inc. grew its position in Castle Biosciences by 11.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 153,907 shares of the company’s stock worth $4,389,000 after purchasing an additional 15,200 shares in the last quarter. Barclays PLC raised its position in Castle Biosciences by 310.7% during the third quarter. Barclays PLC now owns 52,301 shares of the company’s stock valued at $1,491,000 after buying an additional 39,567 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Castle Biosciences in the third quarter worth approximately $1,478,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Castle Biosciences by 16.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 274,761 shares of the company’s stock worth $7,836,000 after buying an additional 39,417 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.